Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.

Br J Cancer · 2005 · PMC2361603 · PMID 16106267

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

marginally significantP =0.07so close (0.05 < p ≤ 0.1)

Although the difference between HER-2 overexpression in the primary tumour and the metastases was marginally significant ( P =0.07), a discordance was observed (Kendall's tau- b coefficient=0.69, 95% CI=0.53–0.80) due to more cases of HER-2 overexpression in the metastases.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.